Browsing Tag
Daratumumab
10 posts
Is Dr. Reddy’s oncology pipeline strong enough to compete with global innovators in 2025 and beyond?
Explore Dr. Reddy’s oncology pipeline, biosimilars approvals, and revenue outlook—can the Hyderabad-based pharma firm compete with global cancer drug innovators?
July 15, 2025
Can Dr. Reddy’s build a biosimilars portfolio that rivals Biocon and global MNCs in regulated markets?
Explore Dr. Reddy’s biosimilars pipeline, regulatory milestones, and commercial strategy—can it compete with Biocon and global pharma giants in 2025?
June 24, 2025
GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma
GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as…
November 28, 2023
Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma
Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA)…
May 28, 2023
Janssen Pharmaceutical’s DARZALEX FASPRO gains FDA approval for AL amyloidosis treatment
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has secured FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj),…
January 16, 2021
Janssen seeks expanded approval for DARZALEX in treating AL amyloidosis
Janssen Pharmaceutical Companies of Johnson & Johnson has recently submitted a Type II variation application to the European…
November 8, 2020
Janssen, Amgen secure FDA approval for DKd regiment in multiple myeloma
DKd regiment FDA approval for multiple myeloma : Janssen Pharmaceutical Companies of Johnson & Johnson and Amgen have…
August 23, 2020
CANDOR clinical trial results : Amgen’s Kyprolis extends PFS in multiple myeloma patients
CANDOR clinical trial results : Amgen said that a phase 3 study assessing Kyprolis (carfilzomib) in combination with…
September 13, 2019
Esketamine nasal spray misses key trial expectations, but Janssen remains optimistic
Janssen Pharmaceutical Companies of Johnson & Johnson encountered a significant setback with their esketamine nasal spray in a…
September 23, 2018
Janssen secures EC approval for daratumumab as new multiple myeloma therapy
The Janssen Pharmaceutical Companies of Johnson & Johnson have achieved a significant milestone with the European Commission’s approval…
September 1, 2018